Protalex is a drug development company currently working to treat autoimmune inflammatory diseases in patients in the United States. Its biopharmaceutical products target diseases, such as rheumatoid arthritis, by binding to and regulating the cells that may compromise healthy cells before the disease gets worse. The company’s lead product for combatting this disease is currently in Phase 1b clinical trials. For more information, please visit the company’s website at www.protalex.com.